- Home
- ICCM vs ACRV Comparison
ICCM vs ACRV Comparison
Compare ICCM & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICCM
- ACRV
- Stock Information
- Founded
- ICCM 2006
- ACRV 2018
- Country
- ICCM Israel
- ACRV United States
- Employees
- ICCM N/A
- ACRV N/A
- Industry
- ICCM
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ICCM
- ACRV Health Care
- Exchange
- ICCM Nasdaq
- ACRV Nasdaq
- Market Cap
- ICCM 49.1M
- ACRV 47.8M
- IPO Year
- ICCM N/A
- ACRV 2022
- Fundamental
- Price
- ICCM $0.71
- ACRV $2.26
- Analyst Decision
- ICCM Strong Buy
- ACRV Buy
- Analyst Count
- ICCM 1
- ACRV 5
- Target Price
- ICCM $2.50
- ACRV $14.67
- AVG Volume (30 Days)
- ICCM 463.0K
- ACRV 1.2M
- Earning Date
- ICCM 11-19-2025
- ACRV 11-13-2025
- Dividend Yield
- ICCM N/A
- ACRV N/A
- EPS Growth
- ICCM N/A
- ACRV N/A
- EPS
- ICCM N/A
- ACRV N/A
- Revenue
- ICCM $2,787,000.00
- ACRV N/A
- Revenue This Year
- ICCM $2.92
- ACRV N/A
- Revenue Next Year
- ICCM $57.81
- ACRV $805.34
- P/E Ratio
- ICCM N/A
- ACRV N/A
- Revenue Growth
- ICCM N/A
- ACRV N/A
- 52 Week Low
- ICCM $0.56
- ACRV $1.05
- 52 Week High
- ICCM $1.66
- ACRV $8.35
- Technical
- Relative Strength Index (RSI)
- ICCM 36.88
- ACRV 58.68
- Support Level
- ICCM $0.66
- ACRV $1.78
- Resistance Level
- ICCM $0.72
- ACRV $2.35
- Average True Range (ATR)
- ICCM 0.04
- ACRV 0.20
- MACD
- ICCM 0.01
- ACRV 0.01
- Stochastic Oscillator
- ICCM 41.49
- ACRV 69.83
About ICCM IceCure Medical Ltd.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.